Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $25.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 234.67% from the stock’s previous close.
ORIC has been the subject of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Thursday, January 22nd. Wells Fargo & Company lifted their target price on shares of Oric Pharmaceuticals from $19.00 to $25.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 target price on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Monday, March 9th. Finally, Wedbush dropped their price objective on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $19.90.
Read Our Latest Research Report on ORIC
Oric Pharmaceuticals Trading Down 41.0%
Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.04. On average, sell-side analysts predict that Oric Pharmaceuticals will post -2.17 EPS for the current fiscal year.
Insiders Place Their Bets
In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 52,000 shares of the firm’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total transaction of $702,520.00. Following the completion of the sale, the chief financial officer owned 68,148 shares of the company’s stock, valued at $920,679.48. This trade represents a 43.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.82% of the company’s stock.
Hedge Funds Weigh In On Oric Pharmaceuticals
Large investors have recently modified their holdings of the business. AQR Capital Management LLC acquired a new stake in shares of Oric Pharmaceuticals during the 1st quarter worth about $276,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Oric Pharmaceuticals by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock worth $226,000 after buying an additional 3,131 shares during the period. Goldman Sachs Group Inc. boosted its stake in Oric Pharmaceuticals by 9.2% during the first quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company’s stock worth $1,645,000 after buying an additional 24,778 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Oric Pharmaceuticals by 1,331.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company’s stock worth $2,841,000 after acquiring an additional 473,600 shares during the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of Oric Pharmaceuticals by 56.0% in the 1st quarter. Jane Street Group LLC now owns 31,198 shares of the company’s stock worth $174,000 after acquiring an additional 11,198 shares during the last quarter. Institutional investors and hedge funds own 95.05% of the company’s stock.
More Oric Pharmaceuticals News
Here are the key news stories impacting Oric Pharmaceuticals this week:
- Positive Sentiment: ORIC selected a recommended Phase 3 dose (rinzimetostat 400 mg once daily) for the Himalayas?1 global registrational trial in post?abiraterone mCRPC and said the Phase 3 is expected to start in 1H 2026 — a clear program advancement toward a potential commercial pathway. ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D…
- Positive Sentiment: Multiple outlets note ORIC is advancing its prostate cancer candidate into Phase III, which de-risks the development pathway relative to earlier stages. Oric to advance prostate cancer drug to Phase III trials
- Neutral Sentiment: Wedbush trimmed its price target from $20 to $17 but kept an Outperform rating — an endorsement of long?term potential, albeit with a more cautious near?term valuation. Benzinga
- Negative Sentiment: Investors reacted to safety and side?effect signals in the Phase 1b combination (rinzimetostat + darolutamide) — reports highlighted tolerability issues at higher doses that complicate dose selection and risk/regulatory discussions. Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down
- Negative Sentiment: Coverage and headlines emphasizing side?effect data and an after?hours tumble amplified selling pressure as the market digests whether the safety profile will limit dosing or commercial advantage. Oric Pharmaceuticals Shares Fall on Side Effect Data in Prostate Cancer Drug Trial
- Negative Sentiment: Analyst/market commentary framed the update as unfavorable to current valuation levels, increasing near?term downside risk until clearer safety/efficacy readouts and Phase 3 design clarity arrive. ORIC Pharmaceuticals: Updates Did Not Bode Well For This Valuation
About Oric Pharmaceuticals
Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.
The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.
See Also
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
